Skin Sub changes are here - are you ready?
From January 1, 2026 there are significant changes to the CTP / Skin Substitute / CAMPs market with a new Payment / Reimbursement Model.
This means that many products will no longer be profitable.
Interested in joining our national network of independent sales professionals?
Why partner with AROA?
To allow you to focus on sales, we will provide training, reimbursement, medical affairs, billing, marketing and logistical support.
While this is primarily an outpatient-focused initiative, there may be an additional opportunity for inpatient sales with our Myriad product range for soft tissue reconstruction in some circumstances.
Ideal for hard-to-heal wounds. Symphony brings together the regenerative properties of our platform technology (AROA ECM™) with hyaluronic acid to advance wound closure.1
Responsible Pricing
Even with a payment of $127.14 / cm², Symphony offers sustainable profitability.
Nationwide GPO Coverage
We are listed on all major GPOs, including Vizient, Premier, HealthTrust, and Ascension, ensuring broad national access to our products.
Versatile Sizing
Ongoing Support
From training and billing to reimbursement support and insurance verification, we offer ongoing services to all our 1099 partners and customers.
DFU Clinical Trial
A randomized controlled trial (RCT) for diabetic foot ulcers (DFUs) concluded at the end of 2025. AROA will be submitting the Symphony data to CMS to secure DFU coverage.
Helps kickstart the healing of chronic wounds. Endoform is a single layer of AROA ECM technology, and is available in Natural and Antimicrobial formats across a range of sizes.
Well-known & Trusted
Endoform has been sold and used in the US for over 12 years with 7+ million devices used in clinical applications.
Covered under DME Benefits
Endoform is widely accessible and also covered under DME benefits.
Continuum of Care
If the wound has not healed following CAMP applications, Endoform can be used to close. This offers patients uninterrupted care using advanced bioscaffold technology.
Backed by Evidence
Symphony and Endoform are both based on AROA ECM technology. This has been studied across a variety of clinical specialties and complex soft tissue deficits.
24
Pre-clinical peer-reviewed publications
81
Peer-reviewed clinical publications
Founded in 2008, AROA is ethically minded and dedicated to unlocking regenerative healing for everybody
Our products are approved for use in over 50 countries
7.6+ million devices used in clinical applications worldwide
Four product families spanning all sites of care
World-leading outcomes
Backed by compelling clinical evidence our products support world-leading outcomes in functional tissue regeneration, even in the most complex wounds.
Widespread impact
Designed for widespread impact, our products are versatile, accessible, and simple to use.
Unmatched value
Our products deliver unmatched value by reducing hospital costs and driving meaningful operational improvements.
Think AROA is a good fit for you?
Complete the form to register your expression of interest to partner with us. We will only use your information to assess your application and we will not share your information without your approval.
Don’t delay, get in early and make sure you are ready for the change.
By submitting this application, you agree that your application will be accepted or declined at AROA’s sole discretion, and acknowledge that AROA will have no liability to you in relation to this application process.
References
1. Smith MJ, et al. Journal of Biomaterials Applications. 2022 Jan;36(6): 996-1010.
